Abstract 429P
Background
The impact of COVID-19 has been concerning in management of the non-COVID diseases, especially cancer. We conducted an online survey to study the impact COVID-19 had on cancer-related care.
Methods
The survey was conducted in collaboration with OncoAlert between March 2022 and June 2022 through google forms which were mainly circulated through the ONCOassist app and other social platforms including emails to various oncology-related specialties.
Results
The online questionnaire was completed by 155 respondents and the majority were males (71%) who were relatively young (85.1% were in the age group 25-45 years). The majority were radiation oncologists (52.3%) and Medical Oncologists (29%). About 3/4th of the centers admitted admit COVID patients in their centers and 81.3% believed cancer care was hampered due to the pandemic. About 79.4% provided telemedicine facilities and 18.8% conveyed that more than 25% of cancer patients were managed by this facility. COVID testing was done before starting therapy with 65.4%, 54.9%, and 52.3% sharing the need for the test prior to surgery, chemotherapy, or the start of radiation therapy respectively. Only 11.1% felt the need to deviate from the standard of care more than 50% of the time. The majority (74.5%) felt there was a delay in diagnosis and 81.7% and 80.4% felt there was progression to advanced stages or patients were lost to follow-up respectively. About 56.9% felt that they provided substandard treatment to their patients. Education and training in oncology too took a hit during the pandemic as examinations for the specialties in oncology needed to be conducted on the online platform (46%). About 22.9%, 10.8%, and 14.2% felt that more than 50% of surgeries, chemotherapy, and radiation treatment needed to be canceled. Unfortunately, 21.8% reported having to make changes in the curative intent of treatment. The recruitment delays and halts (87.5%) were major factors that impacted the oncology-related research and 52.8% did not start new research. About 59.3% have used the Oncoassist mobile application for more than a year.
Conclusions
Decision-making in oncology has been influenced by the COVID-19 pandemic. Telehealth is a novel concept that is being encouraged and used by clinicians to improve patient care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Devnani: Financial Interests, Personal, Invited Speaker, Invited for a lecture in Sabah Rectal cancer summit and recieved 300 dollars for the same: Sabah Rectal Cancer Society, Malaysia; Financial Interests, Personal, Officer, I am chairperson of committee for making Consensus document for management of Melanoma and CNS tumors and member of Survivorship committee: Indian Council of Medical Research; Non-Financial Interests, Personal, Leadership Role, Facebook editor of Oncoalert network: Oncoalert; Non-Financial Interests, Personal, Member, Life time member: Association of Radiation Oncologists of India, Indian Society of Neuro-Oncology; Non-Financial Interests, Personal, Member, Member in 2019-2020: ASTRO; Non-Financial Interests, Personal, Member, Member of Society: Indian Society of Oncology. K.D. Bambury: Financial Interests, Institutional, Invited Speaker, I am a director and full-time employee of ONCOassist. ONCOassist receives sponsorship from various pharmaceutical companies.: ONCOassist; Financial Interests, Personal, Ownership Interest: ONCOassist. G. Morgan: Financial Interests, Personal, Advisory Board, Advisory board: Pfizer, Roche; Financial Interests, Personal, Invited Speaker, Invited lecturer: Novartis; Financial Interests, Personal, Invited Speaker, invited speaker: Astra Zeneca; Non-Financial Interests, Personal, Advisory Role, Advisory Board eESO: ESO; Non-Financial Interests, Personal, Leadership Role, Director of OncoAlert Network: OncoAlert. All other authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06